Relation of HFE gene mutations, high iron stores and early onset coronary artery disease

Canadian Journal of Cardiology

Volumn 14, Issue 2, 1998, Pages 215-220

  Nassar, Bassam A ^a,b   Zayed, Ekram M ^a   Title, Lawrence M ^a   O'Neill, Blair J ^a   Bata, Iqbal R ^a   Kirkland, Susan A ^a   Dunn, Jeremy ^a   Dempsey, Gale I ^a   Tan, Meng Hee ^a   Johnstone, David E ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Coronary artery disease; Ferritin; Genetic mutations

Indexed keywords

FERRITIN; HLA ANTIGEN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FERRITIN BLOOD LEVEL; GENE LOCUS; GENE MUTATION; HUMAN; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; RISK FACTOR;

CORONARY DISEASE; FEMALE; FERRITINS; HEMOSIDEROSIS; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IRON; MALE; MUTATION; SEX FACTORS;

EID: 6844258231     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kannel WB, Castelli WP, Gordon T. Serum cholesterol, lipoproteins and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971;74:1-12.
2. Goldstein JL, Hobbs HH, Brown MT. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease New York: McGraw-Hill, Inc: 1995:1981-2030.
3. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981;40:1-52.
4. Consensus conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080-6.
5. Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. JAMA 1990;264:3047-52.
6. Stamper MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A retrospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
7. Godbount V, Holtzman E, Neufeld HN. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. BMJ 1985;290:1239-43
8. Sullivan JL. Stored iron and ischemic heart disease: empirical support for a new paradigm. Circulation 1992;86:1035-7.
9. Salonen JK, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
10. McCord JM. Is iron sufficiency a risk factor for ischemic heart disease? Circulation 1991;83:1112-24.
11. Cross CE, Halliwell B, Borish ET, et al. Oxygen radicals and human disease. Ann Intern Med 1987;107:526-45.
12. Sullivan JL. The iron paradigm of ischemic heart disease. Lancet 1989;117:1177-88.
13. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;i:1293-4.
14. Schachter F, Faure-Delanef L, Guenot F, et al Genetic associations with human longevity at the apoE and ACE loci. Nat Genet 1994;6:29-32.
15. Proust J, Moulias R, Fumeron F, Bekkhoucha F, Busson M, Schmid M, Hors J. HLA and longevity. Tissue Antigens 1982;19:168-73.
16. Takata H, Suzuki M, Ishii T, Sekiguchi S, in H. Influence of major histocompatibilitv complex region genes of human longevity among Okinawan-Japanese centenarians and nonagenarians. Lancet 1987;ii:824-6.
17. Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B12 antigens with idiopathic hemochromatosis. Gut 1976;17:332-4.
18. Robson KJH, Shearman JD, Merryweather-Clarke AT, et at. Haemochromatosis: a gene at last. J Med Genet 1997;34:148-51.
19. Bulaj ZJ, Griffin LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-805.
20. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
21. Mercier B, Mura C, Ferec C. Putting a hold on HLA-H. Nat Gener 1997;15:234.
22. Bodmer JC, Parham P, Albert ED, Marsh SGE. Putting a hold on HLA-H. Nat Genet 1997;15:234-5.
23. Beutler E, Gelbart T, West C, et al. Mutation analysis in. hereditary hemochromatosis. Blood Cells Mol Dis 1996;22:187-94.
24. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-51.
25. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996;14:251-2.
26. Carella M, D'Ambrosio L, Totaro A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997;60:828-32.
27. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis C282Y mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-3.
28. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutation. Lancet 1997;349:296-7.
29. 2 knockout mice develop parenchymal iron overload: a putative role for the class genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci USA 1996;93:1529-34.
30. Powell LW, Jazwinska EC. Hemochromatosis in heterozygotes. N Engl J Med 1996;335:1837-9.
31. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984;74:1890-4.
32. Sullivan JL, Till GO, Ward PA, Newton RB. Nutritional iron restriction diminishes acute complement-dependent lung injury. Nutr Res 1989;9:625-34.
33. Andrews FJ, Morris CJ, Lewis EJ, Blake DR. Effect of nutritional iron deficiency on acute and chronic inflammation. Ann Rheum Dis 1987;46:859-65.
34. Babbs CF. Role of iron in the genesis of reperfusion injury following successful cardiopulmonary resuscitation: preliminary data and a biochemical hypothesis. Ann Emerg Med 1985;17:777-83.
35. Bernier M, Hearse DJ, Manning AS. Reperfusion-induced arrhythmias and oxygen-derived free radicals: studies with anti-free radical interventions and a free-radical generating system in the isolated perfused rac heart. Circ Res 1986;58:331-40.
36. Lesnefsky EJ, Repine JE, Horwitz LD. Deferoxamine pretreatment reduces canine infarct size and oxidative injury. J Pharmacol Exp Ther 1990;253:1103-8.
37. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994;89:2915-8.
38. Cook FD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976;48:449-55.
39. Jonsson JJ, Johannesson GM, Sigfusson N, Magnusson B, Thjodleifsson S. Prevalence of iron deficiency and iron overload in the adult Icelandic population. J Clin Epidemiol 1991;44:1289-97.
40. Munro HN, Linder MC. Ferritin: structure, biosynthesis, and role in iron metabolism. Physiol Rev 1976;58:317-96.
41. Edwards CQ, Griffin LM, Goldgar D, Drurnmond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318;1355-62.
42. Aldersley MA, Howdle PD, Wyatt JI, Robinson PA, Markham AF. Haemochromatosis gene and mutation in liver disease patients. Lancet 1997;349:1025-6.
43. Kervinen K, Savolainen MJ, Salokannel J, et al. Apolipoprotein E and B polymorphism-longevity factors assessed in nonagenarians. Atherosclerosis 1994;105:89-95.
44. Galinsky D, Tysoe C, Brayne CE, et al. Analysis of the apo E/apo C-I, angiotensin converting enzyme and methvlenetetrahydrofolate reductase genes as candidates affecting human longevity. Atherosclerosis 1997;129:177-83.